Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:23 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 9,942 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

NCT05696080
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, Placebo, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Not listed Phase 4 Interventional

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

NCT00426296
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
atazanavir (Reyataz), ritonavir (Norvir)
Drug
Lead sponsor
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Other
Eligibility
18 Years and older
Timeline
Started 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Nov 3, 2026, 9:23 AM EST
Terminated Phase 2 Interventional Results available

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

NCT01381562
View directory record Official record
Conditions
Infections, Intestinal
Interventions
Drug: GSK2251052, Meropenem, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Mobile, Alabama • Long Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

NCT00001088
View directory record Official record
Conditions
HIV Infections
Interventions
APL 400-047, Bupivacaine hydrochloride
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
4
States / cities
Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 2 Interventional

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

NCT00002127
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Greenbrae, California • Redwood City, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

NCT04405570
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg, Placebo (PBO)
Drug
Lead sponsor
Ridgeback Biotherapeutics, LP
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Northridge, California • Oxnard, California • Yucaipa, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Nov 3, 2026, 9:23 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Can COVID-19 Persist in Intraocular Fluid?

NCT04945850
View directory record Official record
Conditions
Ocular Infection, Viral
Interventions
routine care intraocular sx
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Nov 3, 2026, 9:23 AM EST
Completed No phase listed Observational

PTSD and Risk Behavior in HIV Positive Female Adolescents

NCT00271882
View directory record Official record
Conditions
PTSD, Sexual Abuse, HIV Infections
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Miami, Florida • The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Results available

PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

NCT03070223
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Pitavastatin, Placebos
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Nov 3, 2026, 9:23 AM EST
Withdrawn Phase 4 Interventional

Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1

NCT02485080
View directory record Official record
Conditions
PT-NANBH
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 72 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Palo Alto, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Nov 3, 2026, 9:23 AM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

HIV Prevention and PrEP Intervention for SGM Adolescents and Parents: "Hey, Friend"

NCT04846946
View directory record Official record
Conditions
HIV Infections
Interventions
Hey, Friend
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

NCT00755703
View directory record Official record
Conditions
Influenza A Subtype H5N1 Infection
Interventions
Pandemic Influenza Vaccine, Placebo
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
19 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Nov 3, 2026, 9:23 AM EST
Completed Not applicable Interventional Results available

Hub Cleansing to Prevent Hub Infection

NCT01563406
View directory record Official record
Conditions
Bacteremia
Interventions
15 second scrub, 5 second scrub, 3.15% chlorhexidine/70% isopropyl alcohol, 70% isopropyl alcohol
Other · Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
16 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Nov 3, 2026, 9:23 AM EST
Terminated Phase 1 Interventional Results available

Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study

NCT02531295
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
Euphorbia kansui extract powder prepared as tea
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 1 Interventional

Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration

NCT04673877
View directory record Official record
Conditions
Infection, Hand Injury Wrist, Hand Injuries, Hand Injuries and Disorders, Hand Arthritis
Interventions
Systemic IV Vancomycin, Bier Block, Vancomycin
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of GBS Colonization Via Immunity

NCT00128219
View directory record Official record
Conditions
Beta Haemolytic Streptococcal Infection
Interventions
GBS III-TT, Tetanus and diptheria toxoids vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Nov 3, 2026, 9:23 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

NCT05555030
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
Device · Diagnostic Test
Lead sponsor
New Day Diagnostics
Network
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Anaheim, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Results available

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

NCT02651428
View directory record Official record
Conditions
Kidney Failure, Chronic, Catheter-Related Infections
Interventions
Neutrolin, Heparin
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Nov 3, 2026, 9:23 AM EST
Recruiting Phase 3 Interventional

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

NCT06960928
View directory record Official record
Conditions
Long COVID-19
Interventions
Low-dose sirolimus, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Results available

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

NCT02625909
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 3, 2026, 9:23 AM EST
Completed No phase listed Observational

Bacterial Pulmonary Infection in PICU

NCT00271531
View directory record Official record
Conditions
Bacterial Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Louisville, Kentucky • St Louis, Missouri • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Nov 3, 2026, 9:23 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults

NCT00623753
View directory record Official record
Conditions
HIV Infections
Interventions
EnvDNA, PolyEnv1, EnvPro
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

NCT02578277
View directory record Official record
Conditions
HIV Infections
Interventions
CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

NCT00000675
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 9:23 AM EST